Alembic Pharmaceuticals Reports FY 2024-25 BRSR with 100.00% Turnover from Pharmaceuticals

Alembic Pharmaceuticals Ltd. has released its Business Responsibility and Sustainability Report (BRSR) for the financial year ended 31st March, 2025. The company's operations include manufacturing and trading of active pharmaceutical ingredients and finished dosage formulations, contributing to 100.00% of the total turnover. Alembic's products are marketed in formulations and international generics, catering to various geographies with pharmaceutical companies, healthcare facilities, and pharmaceutical distributors as customers. The company has 57.00% of its turnover coming from international business. Alembic has 437 permanent employees and 10 differently-abled employees, with a 22.22% female participation in the workforce. The company has a presence in 9 locations and serves both national and international markets. Alembic follows CSR initiatives as per Section 135 of the Companies Act, 2013.